Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Frequently asked questions
What sector does Bright Minds Biosciences Inc (DRUG) operate in?
Bright Minds Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Bright Minds Biosciences Inc (DRUG) current stock price?
As of the latest data, Bright Minds Biosciences Inc stock price is CA$109.72, with a previous close of CA$111.70. Bright Minds Biosciences Inc lost -CA$1.98 in the last trading session, representing a -1.77% loss.
What is Bright Minds Biosciences Inc (DRUG) current market capitalization?
Bright Minds Biosciences Inc market cap is approximately 1.08 billion.
What is Bright Minds Biosciences Inc (DRUG) Earnings Per Share (EPS)?
The trailing EPS is -CA$3.42, and the forward EPS is -CA$12.09.
Does Bright Minds Biosciences Inc (DRUG) pay dividends?
No. Bright Minds Biosciences Inc does not pay a dividend.
When is Bright Minds Biosciences Inc (DRUG) next earnings report?
Bright Minds Biosciences Inc is expected to release its next earnings report on June 30, 2026.
What is Bright Minds Biosciences Inc (DRUG) beta (volatility) score?
Bright Minds Biosciences Inc has a beta of 0.091, indicating lower volatility than the overall market.
